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Background: Corn peptides (CPs) are a novel food prepared from corn gluten meal, which is a main by-product of
the corn starch industry. Recently, significant beneficial effects of CPs on early alcoholic liver injury in rats and on
acute alcoholic injury in mice were observed. To our knowledge, the present study is the first report showing that
CPs supplementation has beneficial effects on lipid profile, oxidative stress and alcoholic liver injury in men with
chronic alcohol consumption.
Methods: A 9-week, randomized, double-blind, placebo-controlled study was conducted between September 2011
and August 2012 to assess the hepatoprotective effect of CPs. A total of 161 men were randomized to receive CPs
(n = 53), whey protein (n = 54), or corn starch placebo (n = 54) at the same dose of 2 g twice daily. 146 participants
completed the study. Serum lipid profile, serum markers of liver injury, oxidative stress and inflammation, and fatty
liver based on the results of abdominal ultrasonography were assessed at the beginning and end of the intervention.
Results: CPs supplementation (4 g/d) for 9 weeks significantly lowered serum levels or activities of total cholesterol,
triglyceride, alanine aminotransferase, aspartate aminotransferase, malondialdehyde and tumor necrosis factor-α, and
significantly increased serum activities of superoxide dismutase and glutathione peroxidase, but the same dose of whey
protein and corn starch (placebo) did not demonstrate these effects.
Conclusions: Our results indicate that CPs may have protective effects on alcohol-induced liver damage via
modulation of lipid metabolism and oxidative stress. CPs may potentially be used as a functional food for the
management of alcoholic liver disease in subjects with chronic alcohol consumption.
Keywords: Corn peptides, Hepatoprotective, Oxidative stress, Lipid profile, Alcoholic liver injury, Human studyBackground
It is estimated that almost 4% of all deaths worldwide
are attributable to alcohol, 6.2% for men and 1.1% for
women. The harmful use of alcohol is the leading risk
factor for death in men aged 15–59 [1]. Hepatic steatosis
is the initial stage of alcoholic liver injury, and it can
progress to steatohepatitis, fibrosis, and cirrhosis, which is
the third leading (at 16.6%) cause of alcohol-attributable* Correspondence: hwguo@shmu.edu.cn
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unless otherwise stated.deaths worldwide [1]. A comprehensive understanding of
alcoholic liver disease (ALD) mechanisms is incomplete,
but increasing evidence supports the notion that oxidant
stress plays a crucial role in the progression of ALD to cir-
rhosis [2,3]. Notably, numerous antioxidants have been
shown to protect against the damaging effects of alcohol
in in vitro and in vivo models of ALD [2,4,5]. Therefore,
although abstinence from alcohol is the cornerstone and
long-term goal for the management of all stages of ALD,
the research and development of safe dietary supplements,
such as antioxidants of food origin, to alleviate alcoholic
liver injury is an attractive and important challenge for the
scientific community.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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corn starch industry. More than 840 000 tons of CGM are
produced in China annually. However, CGM is mainly
used as a feedstuff or discarded because of its low water
solubility and severe amino acid imbalance even though it
contains approximately 60% (w/w) protein [6,7]. In recent
years, corn peptides (CPs), a novel food prepared from
CGM by enzymatic hydrolysis, have attracted considerable
interest due to various bioactive properties, including anti-
oxidant activity [6,8-14], improvements in lipid profiles [9]
and the ability to accelerate alcohol metabolism [15,16]
and protect against alcohol-induced liver injury [9,10].
The research and development of CPs might effectively in-
crease the value of CGM in the marketplace. However,
most studies using CPs have been conducted in animals
or in vitro. Human data on the effect of CPs are limited.
Our previous work showed that CPs supplementation
accelerated alcohol clearance (based on blood alcohol
concentration and breath alcohol concentration) in
healthy young men, especially at a dose of 4 g/d (XP,YW,
FL, SZ, FY, YL, MC and HG, unpublished data). This
study assessed the effect of CPs (4 g/d) on lipid profile,
oxidant stress, inflammation and alcoholic liver injury in
men with chronic alcohol consumption and fatty liver.
In addition, convincing evidence indicates that whey
protein (WP), which is one of the most popular pro-
tein supplements on the markets today, may also have
beneficial health effects of antioxidant [17-19], anti-
inflammatory [19], lipid metabolism improvements [19]Figure 1 Study flow design.and hepatoprotection [17,20] including protection against
nonalcoholic fatty liver [21,22]. The amounts of WP ad-
ministered to adult humans in most previous studies have
been 20–60 g [19]. However, WP in the current study was
given orally to subjects (WP group) in the same dose regi-
men as CPs (4 g/d) to compare the effect of the peptide
and protein.
Therefore, the present study evaluated the effects of CPs
supplementation on lipid profile, oxidative stress and alco-
holic liver injury compared to WP and corn starch (placebo)
supplementation in men with chronic alcohol consumption.
In addition to serum markers, ultrasound examination
was performed before and after the interventions to ex-
plore the effect of supplements on fatty liver.
Results
Participant characteristics and compliance
Participant flow and follow-up are given in Figure 1. Of
the 161 participants recruited into the study, 15 withdrew
from the study (9.3%): placebo group (n = 5, 9.3%), WP
group (n = 4, 7.4%) and CPs group (n = 6, 11.3%) (χ2 =
0.485, P = 0.785). Data from the 146 participants who
completed the study were included in subsequent
analyses. Self-reported data from the logs and returned
supplements indicated that participants complied very
well throughout the study. Overall, 90% of the partici-
pants consumed >90.0% of the provided supplements
(see Additional file 1: Table S1). Compliance did not
differ between treatment groups (P = 0.767). No associated
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characteristics are given in Table 1. Demographic and an-
thropometric characteristics of participants did not differ
significantly between groups.
Serum lipid profile
The effects of WP and CPs on lipid profiles are given in
Table 2. At week 9, after adjusting for baseline covariates,
the CPs group had significantly greater reductions in
serum concentrations of triglyceride (TG) (P < 0.001 and
=0.003, respectively) and total cholesterol (TC) (P = 0.007
and 0.035, respectively) from baseline values compared to
the placebo and WP groups. Changes in low-density lipo-
protein cholesterol (LDL-C) and high-density lipoprotein
cholesterol (HDL-C) did not differ between groups.
Serum markers of liver injury
The effects of WP and CPs on liver injury markers are given
in Table 3. At week 9, supplementation with CPs decreased
serum alanine aminotransferase (ALT) and aspartate amino-
transferase (AST), whereas participants who received WP
or placebo showed no significant changes. After adjusting
for baseline, there were significant differences in changes in
ALT (P= 0.003 and 0.021, respectively) and AST (P < 0.001
and =0.014, respectively) in the CPs group compared to the
placebo and WP groups. Changes in other biomarkers, in-
cluding the three serum markers of liver fibrosis hyaluronic
acid (HA), type III precollagen (PC III) and type IV collagen
(IV-C), did not differ between groups.
Serum markers of oxidative stress and inflammation
The effects of WP and CPs on oxidative stress markers




Median 47.0 (39.5 - 52.0)
Weight (kg) 76.8 ± 0.7
BMI (kg/m2) 25.9 ± 0.2
>high school diploma (%) 21 (42.9)
>RMB 40,000 yearly income (%) 19 (38.8)
Cigarette smoker (%) 23 (46.9)
Alcohol consumption (g/day) 44.3 (36.0-39.6)
Duration of consumption (%)
5–10 years 8 (16.3)
10–20 years 17 (34.7)
>20 years 24 (49.0)
BMI, body mass index.
Values are means ± SE (continuous variables, normal distribution), medians with int
numbers with percentages in parentheses (categorical variables). Continuous variables
variables were compared using chi-square test or Kruskal-Wallis H test. Characteristicsand malondialdehyde (MDA) and inflammatory marker
tumor necrosis factor-α (TNF-α) are given in Table 4. At
week 9, after adjusting for baseline, the CPs group had
greater increases in GPx (P < 0.001) and SOD (P < 0.001)
and greater reductions in MDA (P < 0.001 and =0.004, re-
spectively) and TNF-α (P < 0.001, respectively) compared
to the placebo and WP groups. Changes in the four
markers did not differ between WP and placebo groups.
Fatty liver
The effects of WP and CPs on fatty liver are given in
Table 5. The proportions of ultrasound grading of fatty
liver at baseline and week 9 did not differ between groups.
The outcomes of fatty liver in the three groups were simi-
lar. No significant treatment effects on fatty liver at study
termination were observed in the three groups.
Discussion
Previous studies have demonstrated that CPs possess
various bioactive functions, such as anti-hypertension
[23], antioxidant [6,8-14], improvements in lipid profile
[9], facilitation of alcohol metabolism [16,24,25], preven-
tion of hepatocellular carcinoma [26], and protection
against alcohol-[9,10] and other hepatotoxic substances-
induced liver injury [11,12], but limited data are available
for the effect of CPs in humans. The present randomized
trial showed for the first time that CPs supplementation
(4 g/d) for 9 weeks had beneficial effects on alcoholic liver
injury in men with chronic alcohol consumption and fatty
liver, whereas the same dose of WP and placebo did not
have these effects.
During alcohol oxidation by alcohol dehydrogenase,




49.0 (43.8 - 52.0) 45.0 (38.0 - 52.0)
77.2 ± 0.8 78.0 ± 0.9
26.2 ± 0.2 26.4 ± 0.3
16 (32.0) 18 (38.3)
18 (36.0) 23 (48.9)
30 (60.0) 26 (55.3)
45.6 (36.0-60.0) 46.9 (36.0-48.0)
9 (18.0) 4 (8.5)
16 (32.0) 16 (34.0)
25 (50.0) 27 (57.5)
erquartile ranges (continuous variables, skewed distribution) in parentheses or
were compared using one-way ANOVA or Kruskal-Wallis H test, and categorical
did not differ between groups.









Baseline 2.53 (1.84 - 3.68) 2.41 (1.56 - 3.71) 2.61 (1.84 - 4.13) 0.474A
Δ9 weeks −0.13 ± 0.07a −0.25 ± 0.07a −0.57 ± 0.08b <0.001B
TC (mmol/L)
Baseline 5.23 ± 0.13 5.13 ± 0.14 5.42 ± 0.17 0.372A
Δ9 weeks −0.02 ± 0.10a −0.11 ± 0.10a −0.42 ± 0.11b 0.020B
LDL-C (mmol/L)C
Baseline 2.69 ± 0.12 2.90 ± 0.15 2.91 ± 0.18 0.497A
Δ9 weeks 0.05 ± 0.12 −0.10 ± 0.11 −0.23 ± 0.12 0.247B
HDL-C (mmol/L)
Baseline 1.26 ± 0.03 1.27 ± 0.03 1.24 ± 0.03 0.740A
Δ9 weeks 0.02 ± 0.02 0.04 ± 0.02 0.08 ± 0.02 0.055B
TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
Values are means ± SE (baseline, normal distribution), medians with interquartile ranges in parentheses (baseline, skewed distribution) or least square means ± SE
(change values). a,bMean values within a row with unlike superscript letters were significantly different (P < 0.05; ANCOVA followed by the least significant difference
test). AANOVA F-test. BANCOVA with baseline values as a covariate. CCalculated according to the Friedewald formula. Data from participants with TG levels ≥4.52 mmol/L
were excluded from the analyses.
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An increase in the NADH/NAD+ ratio favors the deposits
of TG in the liver and results in steatosis [27,28]. Previ-
ously, Li et al. observed a reduction in the liver TG levels
after CPs supplementation in a mouse model of acute alco-
holic liver injury [10]. Zhang et al. observed a reduction in
serum TC, LDL-C and HDL-C levels after CPs supple-
mentation in a rat model of early alcoholic liver injury [9].
In this study, supplementation with CPs significantly low-
ered serum TC and TG after 9 weeks compared to sup-
plementation with WP and placebo. Overall, our data
consistently showed that CPs improved the lipid pro-
file. Furthermore, the 19.5% reduction in serum TG level
and 8.9% reduction in serum TC level that was observed
in this study is likely clinically significant. Therefore, fur-
ther studies are warranted to confirm the effect of CPs on
lipid profile in humans.
CPs might improve the lipid profile by increasing
NAD+ level. The metabolism of the amino acids, such as
Glu, Leu, Ala, and Pro, in CPs may be capable of supply-
ing NAD+ and modulating the NADH/NAD+ ratio to
change the redox system, which is involved in a series of
metabolic alterations, including hyperlipemia and fatty
liver [24,27,28].
Alcohol-induced hepatic damage is characterized by the
release of hepatic enzymes into the circulatory system. An
elevation of hepatic enzymes in serum indicates cellular
leakage and a loss of functional integrity of cell mem-
branes in the liver [29]. Among these enzymes, serum
AST and ALT activities are the most commonly used
markers of hepatocellular damage/necrosis. Previous stud-
ies demonstrated that CPs decreased serum AST and ALTactivities in rodent models of alcohol- [9,30] and other
hepatotoxic substances-induced liver injuries [11,12].
Our results consistently showed that CPs supplementation
decreased serum AST and ALT activities in men with
chronic alcohol consumption. The hepatoprotective effect
of CPs was also confirmed by histopathological examination
in rodents: alcohol-induced necrotic hepatocytes, character-
ized by cell enlargement, nuclear dissolution, microvesicular
steatosis with inflammatory and cell infiltration, were ame-
liorated to some extent by CPs treatment [9,10].
Alcohol abuse stimulates an overproduction of reactive
oxygen species (ROS), lowers cellular antioxidant levels,
and leads to hepatic apoptosis (the development of ALD)
via oxidative stress mechanism [31]. The precise mecha-
nisms by which CPs protect against alcoholic liver injury
are not clear, but previous studies implicated that an anti-
oxidant mechanism might underlie the hepatoprotective
effects of CPs [9,10].
It is well-known that antioxidant enzymes, such as SOD
and GPx, provide protection against oxidative stress, but
they are easily inactivated by excessive lipid peroxides or
other ROS resulting from acute alcohol-induced liver
damage [29]. Our results are consistent with previous ani-
mal data showing that CPs significantly increased serum
activities of SOD and GPx and significantly decreased
serum levels of MDA (marker of oxidative stress) [6,9-12].
The notable antioxidant activities, free radical-scavenging
activities and reducing power of CPs were also observed in
in vitro assay systems by various research groups [6,8,14].
It was proposed that the observed antioxidant activity may
be due to the presence of some proton-donating peptides
in CPs [8]. A recent study suggested that the pentapeptide









Baseline 13.58 (10.56 - 15.47) 12.12 (10.37 - 14.15) 13.22 (10.94 - 17.33) 0.404A
Δ9 weeks 0.08 ± 0.34 −0.46 ± 0.34 −0.99 ± 0.35 0.100B
ALP (U/L)
Baseline 65.26 (56.75 - 73.02) 63.64 (53.07 - 75.86) 66.61 (60.30 - 76.29) 0.219C
Δ9 weeks −1.09 ± 0.83 −1.05 ± 0.82 −3.23 ± 0.85 0.117B
TP (g/L)
Baseline 64.13 ± 0.60 62.82 ± 0.98 62.00 ± 0.97 0.224A
Δ9 weeks 0.09 ± 0.52 1.24 ± 0.51 0.13 ± 0.53 0.208B
GGT (U/L)
Baseline 67.44 (56.75 - 84.81) 65.34 (53.67 - 78.78) 68.34 (57.51 - 91.81) 0.361C
Δ9 weeks −2.73 ± 1.03 −3.59 ± 1.02 −3.76 ± 1.06 0.753B
ALT (U/L)
Baseline 34.51 (28.96 - 41.48) 32.82 (26.73 - 39.54) 34.47 (28.90 - 44.33) 0.500C
Δ9 weeks 0.31 ± 0.67a −0.40 ± 0.66a −2.61 ± 0.68b 0.007B
AST (U/L)
Baseline 25.73 (20.42 - 33.24) 25.19 (21.04 - 31.98) 27.46 (22.16 - 35.49) 0.496C
Δ9 weeks 0.43 ± 0.69a −0.85 ± 0.69a −3.30 ± 0.71b 0.001B
AST/ALT
Baseline 0.78 (0.69 - 0.90) 0.80 (0.74 - 0.94) 0.78 (0.66 - 0.87) 0.440C
Δ9 weeks −0.02 ± 0.02 0.01 ± 0.02 −0.04 ± 0.02 0.310B
HA (ng/mL)
Baseline 88.69 (69.55 - 98.30) 86.88 (68.66 - 101.78) 82.63 (65.58 - 100.30) 0.677C
Δ9 weeks 2.78 ± 3.21 1.42 ± 3.19 3.67 ± 3.29 0.884B
PC III (ng/mL)
Baseline 72.11 (62.82 - 85.38) 67.14 (56.86 - 79.45) 75.84 (64.65 - 89.05) 0.079A
Δ9 weeks −1.93 ± 1.45 −2.36 ± 1.44 −4.77 ± 1.49 0.344B
IV-C (ng/mL)
Baseline 59.44 (52.78 - 64.22) 58.93 (51.01 - 69.80) 58.60 (52.29 - 70.93) 0.619C
Δ9 weeks −1.57 ± 1.26 −0.10 ± 1.24 −2.23 ± 1.28 0.787B
TB, total bilirubin; ALP, alkaline phosphatase; TP, total protein; GGT, gamma-glutamyltransferase; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
HA, hyaluronic acid; PC-III, type III precollagen; IV-C, type IV collagen.
Values are means ± SE (baseline, normal distribution), medians with interquartile ranges in parentheses (baseline, skewed distribution) or least square means ± SE
(change values). a,bMean values within a row with unlike superscript letters were significantly different (P < 0.05; ANCOVA followed by the least significant difference
test). AANOVA F-test. BANCOVA with baseline values as a covariate. CKruskal-Wallis H test.
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nent of CPs [6]. Future work could be directed toward the
purification and generation of bioactive peptide sequences.
Inflammation also has an important role in the patho-
genesis of ALD [32]. Alcohol can awaken Kupffer cells
to be sensitized by lipopolysaccharides and promote the
production of TNF-α and ROS. These inflammatory medi-
ators contribute to hepatocyte dysfunction, apoptosis, ne-
crosis, and characteristic fibrosis [31,32]. In our study, CPs
supplementation significantly decreased serum TNF-α
levels. This result indicates that an anti-inflammatorymechanism might contribute to the hepatoprotective
effect of CPs.
Our study has some limitations. First, only one dose and
one time point was investigated in this study. The lack of
effects of CPs on fatty liver and other biochemical markers
of liver damage is likely due to the relatively low dose used
and the relatively short period of treatment. More studies
evaluating higher doses for a longer treatment period are
needed. In addition, the absence of efficacy of WP is also
likely due to the relatively low dose regimen we employed.
The results would be more convincing if we had a high-









Baseline 190.48 ± 3.88 184.01 ± 4.79 187.15 ± 4.29 0.571A
Δ9 weeks 4.86 ± 2.63a 9.82 ± 2.60a 24.97 ± 2.68b <0.001B
SOD (U/mL)
Baseline 33.78 (28.59 - 36.64) 33.33 (24.88 - 38.55) 29.33 (25.53 - 34.19) 0.065C
Δ9 weeks −0.16 ± 0.72a 1.42 ± 0.70a 7.83 ± 0.73b <0.001B
MDA (nmol/mL)
Baseline 4.70 (4.36 - 5.30) 4.78 (4.24 - 5.30) 4.64 (4.39 - 5.25) 0.992C
Δ9 weeks −0.08 ± 0.05a −0.20 ± 0.05a −0.41 ± 0.05b <0.001B
TNF-α (pg/mL)
Baseline 95.85 (78.25 - 110.67) 83.24 (68.58 - 121.55) 104.10 (73.55 - 125.62) 0.228C
Δ9 weeks −4.65 ± 2.17a −7.69 ± 2.15a −25.56 ± 2.22b <0.001B
GPx, glutathione peroxidase; SOD, superoxide dismutase; MDA, malondialdehyde.
Values are means ± SE (baseline, normal distribution), medians with interquartile ranges in parentheses (baseline, skewed distribution) or least square means ± SE
(change values). a,bMean values within a row with unlike superscript letters were significantly different (P < 0.05; ANCOVA followed by the least significant difference
test). AANOVA F-test. BANCOVA with baseline values as a covariate. CKruskal-Wallis H test.
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the significance of the results relate to the possible super-
iority of CPs to WP at the same dose with respect to the
attenuation of alcoholic liver injury. CPs might have more
bioactive peptides that contribute to the hepatoprotective
effect than WP. Second, our results pertain to Chinese
males with chronic alcohol consumption and mild or mod-
erate fatty liver. Therefore, extrapolation to other popula-
tions should be performed with great caution. Further
studies are needed to confirm and extend the promising
findings in subjects with more severe alcoholic liver injury
or other diseases involving oxidative stress.
Conclusions
In conclusion, the present study is the first report showing
that CPs supplementation (4 g/d) for 9 weeks has benefi-
cial effects on lipid profile, oxidative stress and alcoholic
liver injury in men with chronic alcohol consumption.Table 5 Effects of treatments on fatty liver
Placebo (n = 49) W
Baseline 9-week Basel
Fatty liver grade
Absent 0 (0) 4 (8.2) 0 (0
Mild 39 (79.6) 35 (71.4) 37 (74





Values are numbers with percentages in parentheses. Fatty liver grade (at baseline andThe consumption of CPs had beneficial effects on liver in-
jury, and regular CPs supplementation may, at the very
least, slow the progression of alcoholic liver injury. Conse-
quently, CPs have the potential to be used as functional




A total of 161 men were recruited from Shandong, China
through fliers posted in the community and word-of-
mouth. The following inclusion criteria were used: age
35–55 years, body mass index (BMI) 20–28 kg/m2, alcohol
consumption >30 g/d for at least 5 years, and ultrasound-
defined fatty liver. Daily alcohol consumption (grams of
ethanol per day) was calculated based on the type, quan-
tity, and frequency of alcoholic drinks reported. Partici-
pants were not eligible if they had medical conditions,hey protein (n = 50) Corn peptides (n = 47)
ine 9-week Baseline 9-week
) 3 (6.0) 0 (0) 4 (8.5)
.0) 34 (68.0) 31 (66.0) 28 (59.6)
.0) 13 (26.0) 16 (34.0) 15 (31.9)
3 (6.0) 5 (10.6)
47 (94.0) 42 (89.4)
0 (0) 0 (0)
9-week) and outcome did not differ between groups (Kruskal-Wallis H test).
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rently or previously (past 6 months) taking medications
and /or dietary supplements known to interfere with liver
function, lipid metabolism and inflammatory processes.
Participants with pre-existing viral hepatitis and drug-
induced liver disease were also excluded. This study was
conducted according to the guidelines established in the
Declaration of Helsinki, and all procedures involving hu-
man participants were approved by the Ethics Committee
of the School of Public Health at Fudan University, Shanghai,
China. All participants gave written informed consent and
received monetary compensation for participation.
Study design
A 9-week, randomized, double-blind, placebo-controlled
study was conducted between September 2011 and August
2012 to assess the hepatoprotective effect of CPs. Potential
participants were first screened by phone followed by
a secondary screening to perform liver ultrasound examin-
ation after an overnight fast. Eligible participants completed
a schedule of blood draws, anthropometric measurements
and a questionnaire regarding personal health, demographic
and alcohol consumption. For practical reasons, the sec-
ondary screening was performed on three consecutive
days because of the ability to test a limited number of sub-
jects. A total of 161 participants were randomized using a
random number generator in Excel software (Microsoft,
Seattle, WA) to receive corn starch placebo (n = 54), WP
(n = 54), or identical CPs capsule (n = 53) at the same dose
of 2 g twice daily. The dose of 4 g/day was adopted
based on our previous drinking study, review of pre-
vious CPs human studies [24,25], and the number of cap-
sules so as not to affect compliance with study protocol.
Each participant was instructed to maintain his habitual
mode of living, including diet, physical activity, and
alcohol consumption, during the study. The number of
supplements not consumed and log reviews were used to
assess compliance. Participants returned at 9 weeks to
provide a fasting blood sample and undergo liver ultra-
sound examination.
Supplements
CPs powder was obtained by sequential treatment of
CGM as previously described [9,10]. Our previous study
showed that the CPs sample was rich in Glu + Gln
(22.72 g kg−1), Leu (16.73 g kg−1), Ala (8.17 g kg−1) and
Pro (6.52 g kg−1), and the average molecular weight of the
hydrolyzed peptides was 354 Da, with the majority
(96.72%) distributed below 1 kDa (XP,YW, FL, SZ, FY, YL,
MC and HG, unpublished data). Whey protein concen-
trate was purchased from Hilmar Inc. (Hilmar TH 8000,
Hilmar, CA, USA). Corn starch placebo was purchased
from Lvran Food Co. Ltd. (Xuzhou, Jiangsu, China). All
CPs, WP and corn starch were packaged as 0.5 g capsules(Capsugel, Suzhou, Jiangsu, China). All capsules were put
into bottles containing 56 capsules (for 1 week) and pack-
aged in color-coded plastic bags containing 4 or 5 bottles
(for 4 or 5 weeks) for distribution to participants. An un-
blinded researcher prepared and masked the samples.
When participants finished a 4-bottle package after the
first 4 weeks, they were given a second 5-bottle package.
Participants were instructed to consume 8 capsules two
times daily with breakfast and dinner.
Anthropometric measurements
Height was measured using a calibrated stadiometer (TZG,
Shanghai, China) with 1-mm precision. Body weight was
measured on a digital scale (CAMRY EB9005L, Zhongshan,
Guangdong, China) in light indoor clothes without shoes.
BMI was derived from height and weight measurements.
Blood measurements
At baseline and week 9, a 12-h fasting morning blood
sample was collected, processed and stored at −80°C using
a standard protocol. All serum marker concentrations or
activities were measured using classical methods and com-
mercial assay kits according to the manufacturers' instruc-
tions. Assay kits for TC, TG, and HDL-C were purchased
from Beijing BHKT Clinical Reagent Co. Ltd. (Beijing,
China). LDL-C concentration was calculated according to
the formula of Friedewald: LDL-C (mmol/L) = TC –
HDL-C - TG/2.2. Assay kits for ALT, AST, total bilirubin
(TB), total protein (TP), gamma-glutamyl transpeptidase
(GGT), alkaline phosphatase (ALP), SOD, GPx and MDA
were purchased from Nanjing Jiancheng Bioengineering
Institute (Nanjing, Jiangsu, China). An ELISA kit for TNF-α
was purchased from Cusabio Biotech Co. (Wuhan, Hubei,
China). Chemiluminescence assay kits for serum liver fi-
brosis markers HA, PC III, and IV-C were purchased from
Beijing Tigsun Diagnostics Co. Ltd. (Beijing, China). Ab-
sorbance was measured using a Bio-Rad 680 microplate
reader (Bio-Rad Co., Hercules, CA, USA). Chemilumines-
cence intensity was monitored on a luminescence reader
(FlexStation 3, Molecular Devices, Sunnyvale, CA, USA).
Concentrations or activities were calculated based on
standard curves. Control samples were run with each
assay for quality control purposes. Within- and between-
day batch variations, determined as the coefficient of vari-
ation, were <10%. Laboratory analyses were performed
blind in respect to the assigned treatment.
Liver ultrasound examination
The diagnosis of fatty liver was based on the results
of abdominal ultrasonography (Logic Q700 MR, GE,
Milwaukee, WI, USA). Ultrasonography was performed
by four experienced radiologists who were blinded to the
study according to standardized criteria ((hepatorenal
echo contrast, liver brightness, deep attenuation, and
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liver was recorded using a numbered scoring system (1 =
absent; 2 =mild; 3 =moderate; and 4 = severe).
Sample size and power calculations
A sample size of 53 subjects per group was initially
chosen to detect a difference of 5 U/ml SOD (assuming
a standard deviation of 8 U/ml) between the placebo
and CPs groups with a two-sided α value of 0.05 and a
power of 80%, allowing for a 25% dropout.
Statistical analysis
Data were checked for normality using the Shapiro-Wilk
test because the sample size was <50. Data are presented
as the means and standard errors for normal variables,
medians and interquartile ranges for log-transformed
variables (serum TG, TB and PC III) and non-normal
variables (age, ALP, GGT, ALT, AST, AST/ALT, HA, IV-C,
SOD, MDA, TNF-α), least square means and standard
errors for change values, and numbers (n) or percentages
(%) for categorical variables. For continuous variables,
baseline values were analyzed using analysis of variance
(ANOVA) or the Kruskal-Wallis H test, and changes from
baseline at 9 weeks were compared with analysis of covari-
ance (ANCOVA) with baseline values as a covariate to re-
duce the effect of differences at baseline. When the overall
results were significant, the least significant difference test
was used to determine which groups differed. For categor-
ical variables, the Kruskal-Wallis H test or chi-square test
were used to evaluate differences between groups. All stat-
istical analyses were performed using the Statistical Package
for the Social Sciences 17.0 (SPSS Inc., Chicago, IL, USA).
P < 0.05 was considered statistically significant.
Additional file
Additional file 1: Table S1. Compliance of the subjects.
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